A share price of Protagonist Therapeutics Inc [PTGX] is currently trading at $58.14, down -5.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTGX shares have gain 3.75% over the last week, with a monthly amount glided 6.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $72. Previously, Goldman started tracking the stock with Neutral rating on December 06, 2024, and set its price target to $47. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $62 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $58 on November 05, 2024. TD Cowen initiated its recommendation with a Buy and recommended $65 as its price target on September 24, 2024. Truist started tracking with a Buy rating for this stock on September 09, 2024, and assigned it a price target of $60. In a note dated October 30, 2023, CapitalOne initiated an Overweight rating and provided a target price of $32 on this stock.
Protagonist Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $33.31 and $61.50. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $58.14 at the most recent close of the market. An investor can expect a potential return of 25.56% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Trailing Twelve Months sales for Protagonist Therapeutics Inc [NASDAQ:PTGX] were 209.18M which represents 33.09% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.08 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.84 points at the first support level, and at 55.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.66, and for the 2nd resistance point, it is at 63.19.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Protagonist Therapeutics Inc [NASDAQ:PTGX] is 16.97. Further, the Quick Ratio stands at 16.97, while the Cash Ratio is 4.75. Considering the valuation of this stock, the price to sales ratio is 17.29, the price to book ratio is 5.41 and price to earnings (TTM) ratio is 81.59.
Transactions by insiders
Recent insider trading involved WILLIAM WADDILL, Director, that happened on Aug 27 ’25 when 4000.0 shares were purchased. President and CEO, PATEL DINESH V PH D completed a deal on Jul 25 ’25 to sell 10415.0 shares. Meanwhile, President and CEO PATEL DINESH V PH D sold 22065.0 shares on Jul 22 ’25.
